基因编辑初创公司Verve Therapeutics（VERV）周二盘前股价大涨80.70%，引发市场广泛关注。这一显著涨幅主要源于一则潜在收购消息。
据英国《金融时报》报道，全球制药巨头礼来公司（Eli Lilly）正在就以高达13亿美元的价格收购Verve Therapeutics进行深入谈判。礼来的收购要约包括向Verve支付近10亿美元的预付款，以及在达到某些临床里程碑后再支付3亿美元。若谈判顺利，这笔交易最快可能在本周内宣布。
Verve Therapeutics目前正在开发一种降低高胆固醇水平的基因疗法，预计将与其他药物联合使用。这项收购将有助于礼来加强其实验性药物研发管线，特别是在基因编辑领域。值得注意的是，这笔交易对Verve极具吸引力，因为收购价格几乎是其当前市值的两倍。这一举动也反映了礼来在行业低迷期的逆势扩张策略，今年以来该公司已经斥资数十亿美元收购多家生物技术公司，专注于实验性药物而非商业化阶段的产品。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.